ArticleJournal of market access & health policy2015
The intangible benefits of vaccination - what is the true economic value of vaccination?
Article in Journal of market access & health policy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Are intersectoral costs considered in economic evaluations of interventions relating to sexually transmitted infections (STIs)? A systematic review.BMC public health · 2022Pooled it
- Article
- Rule of Prevention: a potential framework to evaluate preventive interventions for rare diseases.Journal of market access & health policy · 2023Article
- Acceptance and application of a broad population health perspective when evaluating vaccine.Vaccine · 2022Article
- Survey among Italian experts on existing vaccines' role in limiting antibiotic resistance.Human vaccines & immunotherapeutics · 2021Article
- Article
- A global agenda for older adult immunization in the COVID-19 era: A roadmap for action.Vaccine · 2021Article
- Article
- How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future.Journal of market access & health policy · 2020Review
- Impact of Vaccines; Health, Economic and Social Perspectives.Frontiers in microbiology · 2020Review
- Vaccination programs for older adults in an era of demographic change.European geriatric medicine · 2018Review
- 2. How is the economic assessment of vaccines performed today?Journal of market access & health policy · 2017Review
- The antimicrobial resistance crisis: management through gene monitoring.Open biology · 2016Article
- Role of vaccination in economic growth.Journal of market access & health policy · 2015Article
- The Economic Value of Vaccination: Why Prevention is Wealth.Journal of market access & health policy · 2015Article
- Role of vaccination in the sustainability of healthcare systems.Journal of market access & health policy · 2015Article
- From population to public institutions: what needs to be changed to benefit from the full value of vaccination.Journal of market access & health policy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous economic evaluations of new vaccines largely focussed on a narrow set of benefit categories, including primarily health gains and disease-related medical cost-savings, which probably resulted in underestimates of the true value of these vaccines. Other economic benefits of vaccines could be considered to assess the full economic value of vaccination, such as, for example, impact of the human papillomavirus vaccine on women's fertility through the decrease in precancerous lesions and, therefore, in the number of diagnostic and treatment interventions, which can be associated with an increased risk of subsequent pregnancy complications. Vaccines' impact on resource allocation at hospital level or on antimicrobial resistance, such as pneumococcal conjugate vaccines that have substantially reduced infections due to antimicrobial non-susceptible strains, thereby rendering the residual disease easier to treat, are other examples of intangible benefits of vaccination. These benefits are generally not considered in economic evaluations because they may not be immediately visible and are difficult to quantify. However, they should be taken into consideration in health technology assessments to enable those responsible for healthcare policies to make well-informed decisions on vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.